EntryPoint Capital LLC Raises Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

EntryPoint Capital LLC boosted its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 126.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 55,539 shares of the company’s stock after purchasing an additional 31,020 shares during the period. EntryPoint Capital LLC owned about 0.12% of 4D Molecular Therapeutics worth $309,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new stake in shares of 4D Molecular Therapeutics in the fourth quarter valued at approximately $48,000. PNC Financial Services Group Inc. grew its stake in 4D Molecular Therapeutics by 66.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after buying an additional 3,630 shares in the last quarter. Daiwa Securities Group Inc. raised its holdings in 4D Molecular Therapeutics by 5,291.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock valued at $55,000 after acquiring an additional 9,737 shares during the period. Fox Run Management L.L.C. bought a new position in shares of 4D Molecular Therapeutics in the fourth quarter worth $69,000. Finally, AlphaQuest LLC grew its position in shares of 4D Molecular Therapeutics by 3,665.2% in the fourth quarter. AlphaQuest LLC now owns 14,835 shares of the company’s stock valued at $83,000 after purchasing an additional 14,441 shares in the last quarter. 99.27% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on FDMT shares. Morgan Stanley dropped their price objective on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a report on Monday, January 13th. BMO Capital Markets lowered shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $40.00 to $15.00 in a research report on Monday, January 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 4D Molecular Therapeutics in a report on Saturday, March 22nd. Bank of America cut their price target on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating for the company in a report on Monday, March 10th. Finally, Leerink Partners decreased their price target on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a report on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $30.63.

4D Molecular Therapeutics Trading Down 1.4 %

Shares of 4D Molecular Therapeutics stock opened at $3.56 on Friday. The firm has a market capitalization of $164.84 million, a PE ratio of -1.25 and a beta of 2.83. 4D Molecular Therapeutics, Inc. has a 12 month low of $3.50 and a 12 month high of $34.20. The business’s 50-day moving average price is $4.60 and its 200-day moving average price is $7.17.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.10). As a group, analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.